GSDME and ovarian cancer: As a result, our study found a promising agent for ovarian cancer and illustrated that it can induce pyroptosis through the caspase-3/GSDME pathway, which may have reasonable prospects in overcoming the drug resistance of ovarian cancer and improving the outcomes of these patients.